retatrutide type 2 diabetes trial nct Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Dosing: Early Clinical Trial
Description
Individuals with polycystic ovary syndrome often experience absent or irregular periods, ovarian cysts, infertility, facial hair growth, acne, weight gain, problems with blood sugar metabolism, and may have increased cardiovascular disease risk

The safety of GLP-1RAs and GLP-1/GIP dual agonists during pregnancy constitutes a significant area of concern, especially regarding the management of diabetes and obesity in this population

Fatty liver disease (NAFLD or MASH)

Yes, but do it under medical supervision
